Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Klinično preizkušanje novih vrst zdravljenja v onkologiji - zahtevajmo več!
Authors:ID Šeruga, Boštjan (Author)
Files:.pdf PDF - Presentation file, download (186,62 KB)
MD5: 53CD13B22FCD9D3977B2D15C978F59BC
PID: 20.500.12556/dirros/8780b55d-5476-4893-bbdb-7ea437ac3978
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:V randomiziranih kliničnih raziskavah faze III (RKR), ki jih vse pogosteje sponzorirajo k dobičku naravnane farmacevtske družbe, raziskovalci primerjajo nova protirakava zdravljenja s standardnimi. Če se v RKR novo zdravljenje izkaže za učinkovitejše, je običajno odobreno za uporabo v vsakodnevni klinični praksi. V vlogi zdravstvenih strokovnjakov smo dolžni kritično vrednotiti nova zdravljenja in zahtevati preglednost njihovih prikazanih koristi. Z možnostjo dostopa do protokolov kliničnih raziskav, na podlagi katerih so nova zdravljenja odobrena za uporabo, in z nepristranskim poročanjem o njihovih škodljivih učinkih lahko dodatno izboljšamo preglednost prikazanih koristi novih protirakavih zdravljenj. Raziskovalci in sponzorji bi morali pogosteje opravljati posodobljene in sekundarne analize RKR, saj so lahko vir dodatnih pomembnih izsledkov.
Publication status:Published
Publication version:Version of Record
Year of publishing:2012
Number of pages:str. 27-28, 57
Numbering:Letn. 16, št. 1
PID:20.500.12556/DiRROS-8898 New window
UDC:616-006.6-08
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-WFXIHJLN
COBISS.SI-ID:1318779 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3121
Downloads:737
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Clinical trials of new types of treatment in oncology - demand more!
Abstract:In phase III randomised clinical trials (RCT), which are more and more often sponsored by profit-oriented pharmaceutical companies, the researchers compare the new anti-cancer treatments with the standard ones. If the new treatment proves to be more effective in the RCT, it is usually approved for use in daily clinical practice. As health care professionals, we are obliged to provide critical evaluations of new treatments and demand transparency of their benefits. The transparency of the indicated benefits of new anti-cancer treatments can be additionally improved by providing access to clinical research protocols, based on which the new treatments are approved for use, and impartial reports on their adverse effects. The researchers and sponsors should conduct updated and secondary analyses of RCT more often, as they might be a source of additional significant findings.


Archive

niGradiv

Back